Document Type
Article
Publication Date
5-8-2023
Abstract
Myopericarditis associated with COVID-19 mRNA vaccines has been recognized as an uncommon adverse reaction, especially among young, healthy adult males. Eosinophilic myocarditis is a rare form of inflammation reflecting a hypersensitivity reaction following an inciting event commonly caused by drugs including vaccines. Eosinophilic myocarditis, a subtype of myocarditis, is characterized by eosinophilic myocardial infiltrates. It is usually accompanied by systemic eosinophilia in the form of a drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and is rarely associated with myocyte fibrosis and/or necrosis. In this report, we present a case of biopsy-proven eosinophilic myocarditis in a 24-year-old male patient, likely secondary to COVID-19 mRNA vaccination. To our knowledge, this is the first report to describe delayed eosinophilic myocarditis following the COVID-19 mRNA vaccine. Clinicians should be aware of possible delayed presentation to avoid associated morbidity.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Share Alike 4.0 License.
Recommended Citation
Janga, Chaitra; Patel, Tirth; Al Hennawi, Hussam; Atam, Sarin; Shah, Shreeja Shah; Naeem, Ifrah; Memon, Rahat; and Haas, Donald C., "Delayed Presentation of Biopsy-Proven Eosinophilic Myocarditis Following COVID-19 mRNA Vaccine" (2023). Abington Jefferson Health Papers. Paper 88.
https://jdc.jefferson.edu/abingtonfp/88
PubMed ID
37351099
Language
English
Comments
This article is the author’s final published version in Global Cardiology Science & Practice, Volume 2023, Issue 2, May 2023, Article number e202310.
The published version is available at https://doi.org/10.21542/gcsp.2023.10. Copyright © 2023 Chaitra Janga, Tirth Patel, Hesham Al Hennawi, Sarin Atam, Shreeja Shah, Ifrah Naeem, Rahat Memon, Donald C Haas.